About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Class of Schizophrenic Drugs Unveiled

by VR Sreeraman on September 3, 2007 at 2:32 PM
Font : A-A+

New Class of Schizophrenic Drugs Unveiled

A new class of Schizophrenia drugs, that targets different molecule messengers in the brain, has been unveiled.

Getty psychiatrists have welcomed the drugs, which are the first since 1950.

Advertisement

Clinical trials show that the drugs codenamed LY2140023, produced by Eli Lilly researchers in Indianapolis, Indiana, are as effective as olanzapine, the best currently available drug.

Schizophrenia has a wide range of debilitating symptoms that includes delusions, hallucination, disordered thinking, social withdrawal and emotional 'flatness'.
Advertisement

Current anti-schizophrenia drugs operate in a similar way by cutting down levels of neurotransmitter dopamine in the brain.

However, the drugs do not control the condition in all people and lead to unpleasant side effects.

The new drug is changed in the body into a second compound, called LY404023, which acts by slowing down the activity of a different neurotransmitter, glutamate.

"Our study is the first conclusive evidence for a role of glutamate in the pathophysiology of schizophrenia," Nature quoted James Monn, one of the research team, as saying.

In the trial, 196 schizophrenic patients were administered with LY2140023, olanzapine or a placebo for four weeks. The drugs were roughly equally effective.

"In terms of drug development this is a giant step forward — pretty much the first major step forward since 1952, when chlorpromazine was introduced," Solomon Snyder, a neuropharmacologist at Johns Hopkins University in Baltimore, Maryland said.

The side effects of LY2140023 did not cause weight gain like other current antipsychotic drugs.

Researchers observed the possibility that glutamate system might be involved in schizophrenia, when the drug party drug phencyclidine triggered a temporary psychosis alike to the disease.

Though Monn admits that it is unknown how the new drug causes its antipsychotic actions, it is bio chemically a subtly reaction and operates on on a particular glutamate receptor called mGlu2/3.

The receptor has a feedback loop that works only when the glutamate system is very active.

Source: ANI
LIN/J
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity Drugs Banned in India 

Recommended Reading
Schizophrenia
Schizophrenia is a mental disorder characterized by symptoms of thought, behavior and social ......
INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia
The European Commission granted marketing authorization for INVEGA an atypical antipsychotic ......
Controversy Over Use of Antipsychotic Drugs for Dementia
Antipsychotic drugs are approved mainly for treating schizophrenia and bipolar disorder, but they .....
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use